The in-vitro activity of FK-037, a new broad spectrum injectable cephalosporin.

The in-vitro activity of the parenteral cephem FK-037 was compared to those of cefpirome, ceftazidime, cefuroxime, cefixime, amoxycillin and co-amoxiclav. Against the Enterobacteriaceae FK-037 was generally > or = 16-fold more active than cefuroxime and two- to four-fold more active than ceftazidime and similar in activity to cefpirome. Pseudomonas aeruginosa displayed similar susceptibilities to ceftazidime and FK-037 (MIC90 4 and 8 mg/L respectively).

In vitro activity of RU 29246, the active compound of the cephalosporin prodrug ester HR 916.

The in vitro activity of RU 29246 was compared with those of other agents against 536 recent clinical isolates. The MICs of RU 29246 for 90% of members of the family Enterobacteriaceae tested (MIC90s) were less than 2 micrograms/ml except those for Morganella spp. (16 micrograms/ml) and Proteus spp.

Antimicrobial susceptibilities and beta-lactamase characterization of Capnocytophaga species.

Capnocytophaga species have been associated with a wide variety of infections in both immunocompetent and immunocompromised patients. On the basis of data from antimicrobial susceptibility studies, beta-lactam antibiotics have been considered efficacious therapy. Six of 19 isolates from primarily clinical sources across Canada demonstrated beta-lactamase production, and agar dilution susceptibility testing showed broad resistance to beta-lactam antibiotics.

In vitro activity of L-627, a new carbapenem.

The in vitro activity of L-627, a new parenterally administered carbapenem, was compared with those of imipenem, meropenem, FCE 22101 (a penem), ceftazidime, and ceftriaxone. L-627 was active against members of the family Enterobacteriaceae (MIC for 90% of strains tested [MIC90] ranging from 0.03 to 4 micrograms/ml).

The in-vitro activity of cefdinir (FK482), a new oral cephalosporin.

The in-vitro activity of cefdinir (FK482), an orally absorbed aminothiazolyl cephalosporin, was compared with that of cefuroxime, cefixime, cephalexin, cefaclor and co-amoxiclav. Cefdinir was highly active against Staphylococcus aureus, inhibiting 90% of strains at 0.03 mg/L.